| Title |
18 F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, July 2015
|
| DOI | 10.1007/s00259-015-3118-2 |
| Pubmed ID | |
| Authors |
Chunjing Yu, Donghui Pan, Baoming Mi, Yuping Xu, Lixin Lang, Gang Niu, Min Yang, Weixing Wan, Xiaoyuan Chen |
| Abstract |
We report the biodistribution and radiation dosimetry of an integrin αvβ3 specific PET tracer (18) F-AlF-NOTA-E[PEG4-c(RGDfk)]2) (denoted as (18) F-Alfatide II). We also assessed the value of (18) F-Alfatide II in patients with brain metastases. A series of torso (from the skull to the thigh) static images were acquired in five healthy volunteers (3 M, 2 F) at 5, 10, 15, 30, 45, and 60 min after injection of (18) F-Alfatide II (257 ± 48 MBq). Regions of interest (ROIs) were drawn manually, and the time-activity curves (TACs) were obtained for major organs. Nine patients with brain metastases were examined by static PET imaging with (18) F-FDG (5.55 MBq/kg) and (18) F-Alfatide II. Injection of (18) F-Alfatide II was well tolerated in all healthy volunteers, with no serious tracer-related adverse events found. (18) F-Alfatide II showed rapid clearance from the blood pool and kidneys. The total effective dose equivalent (EDE) and effective dose (ED) were 0.0277 ± 0.003 mSv/MBq and 0.0198 ± 0.002 mSv/MBq, respectively. The organs with the highest absorbed dose were the kidneys and the spleen. Nine patients with 20 brain metastatic lesions identified by MRI and/or CT were enrolled in this study. All 20 brain lesions were visualized by (18) F-Alfatide II PET, while only ten lesions were visualized by (18) F-FDG, and 13 by CT. F-Alfatide II is a safe PET tracer with a favorable dosimetry profile. The observed ED suggests that (18) F-Alfatide II is feasible for human studies. (18) F-Alfatide II has potential value in finding brain metastases of different cancers as a biomarker of angiogenesis. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 3% |
| United States | 1 | 3% |
| Unknown | 29 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 23% |
| Student > Master | 5 | 16% |
| Researcher | 4 | 13% |
| Student > Bachelor | 3 | 10% |
| Other | 2 | 6% |
| Other | 1 | 3% |
| Unknown | 9 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 6 | 19% |
| Medicine and Dentistry | 5 | 16% |
| Neuroscience | 5 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Other | 4 | 13% |
| Unknown | 8 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 July 2015.
All research outputs
#14,882,733
of 23,806,312 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#1,782
of 3,083 outputs
Outputs of similar age
#137,987
of 264,789 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#20
of 61 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,789 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 61 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.